The Prevelance of Pulmonary Manifestation in Patients Wit... | NCT04613466

Studies
The Prevelance of Pulmonary Manifestation in Patients With Inflammatory Bowel Disease

NCT04613466

Sponsor

Assiut University

Status

Unknown status

Last Update Posted

Nov 13, 2020Actual

Enrollment

60Estimated

Phase

Not provided

Conditions

The Prevelance and Complications of Pulmonary Manifestations in Patients With Inflammatory Bowel Disease

Interventions

Not provided

Countries

Not provided

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Nov 2020

Overall Recruitment Status or Expanded Access Status

Unknown status

Last Known Status

Not yet recruiting

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Dec 1, 2020Estimated

Primary Completion Date

Dec 1, 2021Estimated

Completion Date

Jun 1, 2022Estimated

First Submitted Date

Oct 28, 2020

First Submission Date that Met QC Criteria

Oct 28, 2020

First Posted Date

Nov 3, 2020Actual

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Nov 10, 2020

Last Update Posted Date

Nov 13, 2020Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Not provided

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

Bronchopulmonary manifestations signs and symptoms are variable extraintestinal manifestations of IBD.

Detailed Description

Several cases like bronchiactsis, bronchitis, tracheobronchitis and broncholitis. None of this complications are specific for either crohns or ulcerative , however the majority of cases are related to ulcerative colitis.

Design Module

Study Type

Observational

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Target Follow-Up Duration

Not provided

Phases

Not provided

Interventional Study Design

Allocation

Not provided

Intervention Model

Biospecimen

No data available

No data is available for this block.

Enrollment

60Estimated

Measure	Description	Time Frame
The presence of pulmonary manifestations in IBD patients		1 year

Eligibility Module

Eligibility Criteria

Inclusion Criteria:All patients diagnosed ulcerative colitis and crohns disaese on conventional treatment and biological treatment -

Exclusion Criteria:no exclusion criteria

Accepts Healthy Volunteers

Not provided

Sex

All

Sex/Gender Based

Yes

Sex/Gender Description

rural or urban

Minimum Age

18 Years

Maximum Age

60 Years

Standard Ages

Adult

Study Population

All patients diagnosed IBD either male or female age 18 to 60 years

Sampling Method

Probability Sample